Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Bought by Hennessy Advisors Inc.

Hennessy Advisors Inc. increased its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 6.8% during the 4th quarter, HoldingsChannel reports. The fund owned 1,670,600 shares of the company’s stock after acquiring an additional 106,600 shares during the quarter. Hennessy Advisors Inc.’s holdings in Amneal Pharmaceuticals were worth $13,231,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Gladius Capital Management LP acquired a new position in shares of Amneal Pharmaceuticals in the 3rd quarter valued at approximately $37,000. DekaBank Deutsche Girozentrale bought a new stake in shares of Amneal Pharmaceuticals in the second quarter worth $42,000. Quest Partners LLC acquired a new stake in Amneal Pharmaceuticals in the third quarter valued at $84,000. Xponance Inc. bought a new position in Amneal Pharmaceuticals during the 2nd quarter valued at $65,000. Finally, Quadrature Capital Ltd acquired a new position in Amneal Pharmaceuticals during the 3rd quarter worth $169,000. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Insider Transactions at Amneal Pharmaceuticals

In other news, SVP Jason B. Daly sold 43,657 shares of the business’s stock in a transaction on Friday, November 15th. The shares were sold at an average price of $8.61, for a total transaction of $375,886.77. Following the completion of the transaction, the senior vice president now owns 13,665 shares of the company’s stock, valued at approximately $117,655.65. The trade was a 76.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Gautam Patel sold 17,410 shares of the stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $8.01, for a total transaction of $139,454.10. Following the completion of the sale, the director now directly owns 2,031,476 shares in the company, valued at approximately $16,272,122.76. This trade represents a 0.85 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 123,657 shares of company stock worth $1,016,687. 17.46% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. StockNews.com lowered shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, December 19th. Truist Financial increased their target price on Amneal Pharmaceuticals from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Wednesday, October 2nd. Finally, Piper Sandler boosted their price target on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an “overweight” rating in a report on Monday, November 11th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $10.00.

Amneal Pharmaceuticals Price Performance

Shares of NASDAQ AMRX opened at $8.31 on Friday. The firm’s 50-day moving average price is $8.20 and its two-hundred day moving average price is $8.08. Amneal Pharmaceuticals, Inc. has a 52-week low of $5.01 and a 52-week high of $9.48.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.